Atyr Pharma Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Atyr Pharma Inc's ROI in the second quarter of 2026?
Atyr Pharma Inc recorded a cumulative net loss of $-61 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -92.52%.

Within the Healthcare sector 327 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 4238 to 4573.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-7.34 %	-3.91 %	-1.28 %	-6.84 %	-19.77 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	58	58	67	80	74
Return On Investment (TTM)	-92.52 %	-100.35 %	-100.14 %	-100.63 %	-93.95 %
ATYR's Overall Ranking	# 4573	# 4238	# 3162	# 3455	# 3548
Seq. Investment Change TTM	-5.81 %	-5.72 %	-0.85 %	5.25 %	-2.33 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-61	-70	-74	-75	-67

ATYR Company Profile >> Back to ATYR Roi Comparisons >> See Annual ATYR Return On Investment

Return On Investment ATYR's Ranking
Within:	No.
Industry	# 50
Sector	# 328
Overall	# 4573

Return On Investment Statistics
High	Average	Low
172.86 %	-56.06 %	-100.63 %
(Dec 31 2015)		(Sep 30 2025)

Financial Statements
Atyr Pharma Inc's II. Quarter Investments	$ 58 Millions	ATYR's Balance sheet
Atyr Pharma Inc's II. Quarter Income	$ -10 Millions	Quarterly ATYR's Income Statement
ATYR's Income by Division		See ATYR's Income by Division

ATYR Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	67	70	90	71	109
Y / Y Investment Growth	-3.66 %	-22.86 %	26.97 %	-34.98 %	234.44 %
Net Income in Millions	-74	-64	-50	-45	-34
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-110.47 %	-91.93 %	-55.82 %	-63.77 %	-30.89 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ATYR's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ATYR's Competitors
Subscribers only: Roi for Atyr Pharma Inc's Suppliers
Subscribers only: Return On Investment for ATYR's Customers

Other Ratios
ATYR's Roa	ATYR's Inventory Turnover Ratio	ATYR's Growth Rates	ATYR's Dividend Statistics
	ATYR's Profitability Ratios	ATYR's Asset Turnover Ratio	ATYR's Dividend Growth
ATYR's Roe	ATYR's Valuation Ratios	ATYR's Financial Strength Ratios	ATYR's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-08-14T08:40:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.